Status:
WITHDRAWN
Creation of Bone Marrow Microenvironment for Treatment of Myelodysplastic Syndrome (MDS) in Conjunction With Allogeneic Stem Cell Transplantation
Lead Sponsor:
Hadassah Medical Organization
Conditions:
Myelodysplastic Syndromes
Myelofibrosis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Normal bone marrow function depends on the coexistence of normal hematopoietic stem cells and a microenvironment mostly located in the medullary part of the bones. Stem cells cannot function properly ...
Eligibility Criteria
Inclusion
- Patients with impaired marrow stem cells by cytogenetic analysis or morphology (blasts), considered normal candidates for allogeneic BMT. Such patients will also be entitled to allogeneic bone marrow transplantation with intraosseous DBM.
- Patients with documented myelofibrosis will be entitled to allogeneic bone marrow transplantation with intraosseous DBM.
Exclusion
- Patients with anticipated life expectancy of \< 4 weeks.
- Pregnant or lactating women.
- Patients with an unrelated disease or relevant clinical problem that may not permit evaluation of the results of the study.
- Patients under 18 years old.
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00148980
Start Date
April 1 2003
Last Update
April 28 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hadassah Medical Organization
Jerusalem, Israel, 91120